Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma

While molecular subtypes of glioblastoma (GBM) are defined using gene expression and mutation profiles, we identify a unique subpopulation based on addiction to the high-affinity glucose transporter, Glut3. Although Glut3 is a known driver of a cancer stem cell phenotype, direct targeting is complic...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer cell Ročník 32; číslo 6; s. 856
Hlavní autoři: Cosset, Érika, Ilmjärv, Sten, Dutoit, Valérie, Elliott, Kathryn, von Schalscha, Tami, Camargo, Maria F, Reiss, Alexander, Moroishi, Toshiro, Seguin, Laetitia, Gomez, German, Moo, Jung-Soon, Preynat-Seauve, Olivier, Krause, Karl-Heinz, Chneiweiss, Hervé, Sarkaria, Jann N, Guan, Kun-Liang, Dietrich, Pierre-Yves, Weis, Sara M, Mischel, Paul S, Cheresh, David A
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 11.12.2017
Témata:
Animals
Antineoplastic Agents - pharmacology
Brain Neoplasms - metabolism
Brain Neoplasms - mortality
Cell Line, Tumor
Gene Expression Profiling
Glioblastoma - metabolism
Glioblastoma - mortality
Glucose Transporter Type 3 - metabolism
Humans
Integrin alphaVbeta3 - metabolism
Kaplan-Meier Estimate
Mice
Mice, Nude
Signal Transduction
Snake Venoms - pharmacology
Transcriptome
Xenograft Model Antitumor Assays
glioblastoma
cancer stem cells
Glut3
integrin
glucose metabolism
ISSN:1878-3686, 1878-3686
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:While molecular subtypes of glioblastoma (GBM) are defined using gene expression and mutation profiles, we identify a unique subpopulation based on addiction to the high-affinity glucose transporter, Glut3. Although Glut3 is a known driver of a cancer stem cell phenotype, direct targeting is complicated by its expression in neurons. Using established GBM lines and patient-derived stem cells, we identify a subset of tumors within the "proneural" and "classical" subtypes that are addicted to aberrant signaling from integrin αvβ3, which activates a PAK4-YAP/TAZ signaling axis to enhance Glut3 expression. This defined subpopulation of GBM is highly sensitive to agents that disrupt this pathway, including the integrin antagonist cilengitide, providing a targeted therapeutic strategy for this unique subset of GBM tumors.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1878-3686
1878-3686
DOI:10.1016/j.ccell.2017.10.016